Big Think
@bigthink·8.8M subscribers·10.1K videos
Exploring the Future Frontiers of Human Health, with Francois Nader | Big Think.
Posted
February 10, 2015
Views
12,946
Likes
242
Comments
87
Engagement
2.54%
February 10, 2015
12,946
242
87
2.54%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
3:01Now PlayingExploring the Future Frontiers of Human Health,
Watch the newest video from Big Think
Join Big Think Edge for exclusive videos
----------------------------------------------------------------------------------
The President & CEO of NPS Pharmaceuticals predicts tremendous growth for the pharmaceutical industry in the coming years as new cures and treatments are developed. He also speaks about the broad scope of pharmaceutical research. The coming decades will see advances in treating minor issues such as the common cold, as well as broad steps forward in the fight against the frightening destruction of Alzheimer's disease.
The biggest challenge moving forward, says Nader, is for regulators to keep up with the radical growth and achievements sure to come. Policy and science need to remain on the same page in order to maximize the positive effects of research.
----------------------------------------------------------------------------------
FRANCOIS NADER:
Francois Nader, MD, has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharma since 2008. During his tenure, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide.
Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS Pharma in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.
Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee. Dr. Nader is the immediate past chair of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry. He is also a Board member of the Biotechnology Industry Organization (BIO), the New Jersey Chamber of Commerce, Trevena, Inc., Clementia Pharmaceuticals, Inc. and Acceleron Pharma Inc. In 2013, Dr. Nader was recognized as the Ernst and Young National Life Science Entrepreneur of the Year.
----------------------------------------------------------------------------------
TRANSCRIPT:
Francois Nader: I think we have tremendous, tremendous growth, tremendous potential in exploring the frontier of human beings. We are just at the very, very beginning of a very exciting adventure. And think of diseases as common cold, right. There is nothing terribly unusual about common cold, right. Yet we don’t have a cure for common cold yet, okay. Which is kind of ironic, right. Which means that innovation could be very small for small things like common cold or big things like Alzheimer’s and diabetes. We have multiple products for the diabetes today. We don’t have a cure for diabetes yet. Actually if you add Alzheimer’s and diabetes it could bankrupt our healthcare system. Yet we don’t have a cure for diabetes and we don’t know how to deal with Alzheimer’s yet. So if I look at the future a couple of things will happen.
One, we have phenomenal tools that will enable us to diagnose and to be more specific in better understanding the mechanism of virtually any disease. And the second aspect would be based on that we can start now, charter the road to better understanding the brain which will be a huge advancement.
We don’t know much about the brain. We know a few things here and there. But the brain is a huge unknown scientifically still. We don’t have a lot of tools yet to better understand how we think, the memory and everything related to our behavior. So the brain will be probably the next frontier.
But we should not forget that we have still about 6,000 rare diseases that do not have a treatment so we have a lot of work to do. And we cannot do it alone. I mean money and investment is one thing but we need to continue working on the framework of the regulatory agencies and how we can partner with the regulators to have a clearer path forward to having the new drugs approved.....
To read the transcript, please go to
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
